Lumida
/KIDS
⌘K
OrthoPediatrics Corp

OrthoPediatrics Corp

KIDS
$22.06USD↑+2.32%+0.50 today

MARKET CAP

576.0M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$21 – $22

52W RANGE

$14
$27

AI Summary

Stalk
Sell NowHigh

KIDS remains in a Stage 4 decline with confirmed lower highs and lows and price below all key moving averages; there are no signs of selling exhaustion, volume and volatility support further downside, and both medium- and short-term signals align with a bearish continuation, favoring selling on breakdown into the next support area.

  • ↑Q2 2026 revenue grew 15% YoY to $70.5M, led by trauma and deformity products.
  • ↑Launched 3P Pediatric Plating Platform Hip System; management expects revenue to build further.
  • ↓Net losses persist; weak profitability metrics raise questions on long-term returns.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

OrthoPediatrics Corp. (NASDAQ: KIDS) is a leading medical device company focused on developing anatomically appropriate implants and instruments for pediatric orthopedic conditions. The company's product portfolio addresses critical areas including trauma, deformity correction, scoliosis, and sports medicine. With its specialized offerings, OrthoPediatrics is strategically positioned within the healthcare industry, aiming to improve clinical outcomes for children and occupying a unique niche within the broader orthopedic market.

Bull says

  • ↑Q2 2026 revenue grew 15% YoY to $70.5M, led by trauma and deformity products.
  • ↑Launched 3P Pediatric Plating Platform Hip System; management expects revenue to build further.
  • ↑International revenue increased 22% YoY to $15.7M following EU MDR approvals.
  • ↑Analysts maintain 'Buy' ratings with average price target implying ~33% upside.
  • ↑Free cash flow usage declined 78% YoY; breakeven or positive cash flow forecast for 2026.
  • ↑Strong balance sheet resilience and positive earnings revisions underpin growth momentum.

Bear says

  • ↓Net losses persist; weak profitability metrics raise questions on long-term returns.
  • ↓Scoliosis segment revenue dropped 9% YoY due to timing and unit shipment gaps.
  • ↓High short interest underscores investor skepticism and potential share price volatility.
  • ↓Market size constraints and intense competition may limit pediatric orthopedic expansion.
  • ↓Timing-dependent revenue streams risk uneven quarterly results and complicate forecasting.
  • ↓Negative earnings yield and poor profitability factors signal significant financial headwinds.

Earnings Call · Q4 2024 · Mgmt. Guidance

Updated 04-29-2026neutral

Transcript signals

Bull points

  • During the fourth quarter, we helped more than 34,000 kids and over 138,000 kids in the full year, both record highs for Orthopediatrics.
  • we anticipate our continued execution will lead to a dominant market share position in trauma and deformity correction and scoliosis implants in the coming five years.
  • Given the OPSB business is generating a higher contribution margin than our implant business, these investments will enable us to generate increased EBITDA and improve cash flows.

Bear points

  • the company's actual results may differ materially.
  • the non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as substitute for orthopediatrics financial results prepared in accordance with GAAP.
  • the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast today, March 4th, 2025.
Read full transcript analysis ›